Sentinel lymph node biopsy during radical prostatectomy in patients with prostate cancer: literature review
- Authors: Izmailov A.A.1,2, Chaprak A.B.1, Garifullin A.I.1, Izmailov A.A.3, Khasiev A.R.1, Farganov A.R.1, Akchulpan T.K.1, Gantsev K.S.1,2, Yatsenko T.G.1, Khrizman Y.N.1
-
Affiliations:
- Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
- Bashkir State Medical University, Ministry of Health of Russia
- Moscow City Oncology Hospital No. 62, Moscow Healthcare Department
- Issue: Vol 21, No 4 (2025)
- Pages: 162-168
- Section: REVIEWS
- Published: 27.02.2026
- URL: https://oncourology.eco-vector.com/oncur/article/view/1927
- DOI: https://doi.org/10.17650/1726-9776-2025-21-4-162-168
- ID: 1927
Cite item
Full Text
Abstract
Prostate cancer is one of the most frequently diagnosed oncological diseases worldwide and in the Russian Federation. Modern extended pelvic lymph node dissection is the most reliable method for detecting metastases in regional lymph nodes in patients with prostate cancer. However, this method is associated with certain risks both during the operation and in the postoperative period, which encourages researchers to develop alternative diagnostic approaches. One such alternative is sentinel lymph node biopsy, which demonstrates high potential in diagnostics. At the same time, a number of factors must be considered: limited number of randomized clinical trials, diversity of protocols used, variability of radioisotope and tracer combinations, as well as the need to consider both instrumental and clinical data. For the widespread implementation of this approach in clinical practice, further scientific research is required, including studies conducted in Russia.
About the authors
A. A. Izmailov
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa; Bashkir State Medical University, Ministry of Health of Russia
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0002-8461-9243
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054; 3 Lenina St., Ufa 450008
A. B. Chaprak
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Email: garifullin.airat@gmail.com
ORCID iD: 0009-0008-3906-6521
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
Airat I. Garifullin
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Author for correspondence.
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0002-7616-3899
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
A. A. Izmailov
Moscow City Oncology Hospital No. 62, Moscow Healthcare Department
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0001-5836-0066
Russian Federation, 27 Istra, Moscow Region 143423
A. R. Khasiev
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0001-9142-480X
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
A. R. Farganov
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Email: garifullin.airat@gmail.com
ORCID iD: 0009-0005-4019-9602
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
T. Kh. Akchulpan
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0002-3627-0067
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
K. Sh. Gantsev
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa; Bashkir State Medical University, Ministry of Health of Russia
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0002-7562-5684
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054; 3 Lenina St., Ufa 450008
T. G. Yatsenko
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Email: garifullin.airat@gmail.com
ORCID iD: 0000-0002-8582-2526
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
Yu. N. Khrizman
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa
Email: garifullin.airat@gmail.com
ORCID iD: 0009-0006-5825-7484
Russian Federation, 73/1 Prospekt Oktyabrya, Ufa 450054
References
- Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
- State of oncological care in Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).
- NCCN Guidelines. Prostate Cancer. Version 1. 2025.
- Clinical guidelines. Prostate cancer. Ministry of Health of Russia, 2021–2022–2023 (20.01.2023). (In Russ.).
- Heidenreich A., Varga Z., von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
- Joniau S., Van Den Bergh L., Lerut E. et al. Mapping of pelvic lymph node metastases in prostate cancer.
- Barth P.J., Gerharz E.W., Ramaswamy A., Riedmiller H. The influence of lymph node counts on the detection of pelvic lymph node metastasis in prostate cancer.
- Cacciamani G.E., Maas M., Nassiri N. et al. Impact of pelvic lymph node dissection and its extent on perioperative morbidity in patients undergoing radical prostatectomy for prostate cancer: a comprehensive systematic review and meta-analysis.
- Ventimiglia E., Briganti A., Montorsi F. Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications.
- Esen T., Esen B., Yamaoh K. et al. De-escalation of therapy for prostate cancer.
- Van Leeuwen P.J., Emmett L., Ho B. et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
- Stabile A., Pellegrino A., Mazzone E. et al. Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard.
- Hope T.A., Eiber M., Armstrong W.R. et al. Diagnostic accuracy of -PSMA-11' target='_blank'>http://www.w3.org/1998/Math/MathML">
68 Ga -PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 2021;7(11):1635. doi: 10.1001/jamaoncol.2021.3771 - Meijer D., Van Leeuwen P.J., Roberts M.J. et al. External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study.
- Acar C., Kleinjan G.H., Van Den Berg N.S. et al. Advances in sentinel node dissection in prostate cancer from a technical perspective.
- Dogan N.U., Dogan S., Favero G. et al. The basics of sentinel lymph node biopsy: anatomical and pathophysiological considerations and clinical aspects.
- Gould E.A., Winship T., Philbin P.H., Kerr H.H. Observations on a “sentinel node” in cancer of the parotid.
- Wawroschek F., Vogt H., Weckermann D. et al. The sentinel lymph node concept in prostate cancer – first results of gamma probe-guided sentinel lymph node identification.
- Rossin G., Zorzi F., De Pablos-Rodríguez P. et al. Sentinel lymph node biopsy in prostate cancer: an overview of diagnostic performance, oncological outcomes, safety, and feasibility.
- Małkiewicz B., Kiełb P., Kobylański M. et al. Sentinel lymph node techniques in urologic oncology: current knowledge and application.
- Fumadó L., Abascal J.M., Mestre-Fusco A. et al. Sentinel lymph node biopsy in prostate cancer patients: results from an injection technique targeting the index lesion in the prostate gland.
- Van Den Berg N.S., Buckle T., Kleinjan G.I. et al. Hybrid tracers for sentinel node biopsy. PMID: 24835293
- Vermeeren L., Muller S.H., Meinhardt W. et al. Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer.
- Wit E.M.K., Van Beurden F., Kleinjan G.H. et al. The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection. Eur J Nucl Med Mol Imaging 2022;49(5):1743–53. doi: 10.1007/s00259-021-05580-0
- Doughton J.A., Hofman M.S., Eu P. et al. A First-in-human study of -nanocolloid' target='_blank'>http://www.w3.org/1998/Math/MathML">
68 Ga -nanocolloid PET/CT sentinel lymph node imaging in prostate cancer demonstrates aberrant lymphatic drainage pathways. J Nucl Med 2018;59(12):1837–42. doi: 10.2967/jnumed.118.209171 - Yuen K., Miura T., Sakai I. et al. Intraoperative fluorescence imaging for detection of sentinel lymph nodes and lymphatic vessels during open prostatectomy using indocyanine green. J Urol 2015;194(2):371–7. doi: 10.1016/j.juro.2015.01.008
- Van Der Poel H.G., Buckle T., Brouwer O.R. et al. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 2011;60(4):826–33. doi: 10.1016/j.eururo.2011.03.024
- Wit E.M.K., KleinJan G.H., Berrens A.C. et al. A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients. Eur J Nucl Med Mol Imaging 2023;50(9):2861–71. doi: 10.1007/s00259-023-06191-7
- Manny T.B., Patel M., Hemal A.K. Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green. The initial clinical experience in 50 patients. Eur Urol 2014;65(6):1162–8. doi: 10.1016/j.eururo.2013.11.017
- Povoski S.P., Neff R.L., Mojzisik C.M. et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 2009;7(1):11. doi: 10.1186/1477-7819-7-11
- Harke N.N., Godes M., Wagner C. et al. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial. World J Urol 2018;36(11):1817–23. doi: 10.1007/s00345-018-2330-7
- Holl G., Dorn R., Wengenmair H. et al. Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging 2009;36(9):1377–82. doi: 10.1007/s00259-009-1157-2
- Sadeghi R., Tabasi K.T., Bazaz S.M.M. et al. Sentinel node mapping in the prostate cancer: meta-analysis. Nuklearmedizin. 2011;50(03):107–15. doi: 10.3413/nukmed-0339-10-07
- Wit E.M.K., Acar C., Grivas N. et al. Sentinel node procedure in prostate cancer: a systematic review to assess diagnostic accuracy. Eur Urol 2017;71(4):596–605. doi: 10.1016/j.eururo.2016.09.007
- Aoun F., Albisinni S., Zanaty M. et al. Indocyanine green fluorescence-guided sentinel lymph node identification in urologic cancers: a systematic review and meta-analysis. Minerva Urol Nefrol 2018;70(4). doi: 10.23736/S0393-2249.17.02932-0
- Urabe F., Kimura S., Yasue K. et al. Performance of indocyanine green fluorescence for detecting lymph node metastasis in prostate cancer: a systematic review and meta-analysis. Clin Genitourin Cancer 2021;19(5):466.e1–9. doi: 10.1016/j.clgc.2021.03.013
- Ma S., Sun J., Xu J. et al. The diagnostic performance of indocyanine green for the sentinel node biopsy in prostate cancer: a systematic review and meta-analysis. Asian J Urol 2025;12(1):1–14. doi: 10.1016/j.ajur.2024.07.001
- Krzhivitsky P.I., Kanaev S.V., Novikov S.N. et al. The use of SPECT-CT for visualization of sentinel lymph nodes and lymph drainage pathways in prostate cancer patients. Voprosy onkologii = Problems of Oncology 2016;62(2):272–6. (In Russ.). doi: 10.37469/0507-3758-2016-62-2-272-276.
Supplementary files


